| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Neochlorogenic acid is a natural polyphenolic substance that has anti-inflammatory properties. It can be separated from plants and dried fruits. Neochlorogenic acid has the ability to block TNF-α and IL-1β production as well as COX-2 and iNOS expression.
| Targets |
p65; IL-1; IL-1β; COX-2
|
|---|---|
| ln Vitro |
Neochlorogenic acid (NCA) inhibits the expression of the proteins iNOS and COX-2 as well as the production of pro-inflammatory cytokines like TNF-α and IL-1β in BV2 microglia cells, thereby reducing the NO production caused by lipopolysaccharide (LPS). Neochlorogenic acid also inhibits phosphorylated p38 MAPK and NF-κB p65 in activated microglia. In LPS-induced BV2 cells, iNOS and COX-2 levels rise; however, after being treated with 50 and 100 μM Neochlorogenic acid, this rise is markedly inhibited[1].
|
| Cell Assay |
Mouse BV2 microglial cells are maintained in DMEM supplemented with 5% FBS and 1% antibiotic-antimycotic in a humidified incubator with 5% CO2 at 37°C. Neochlorogenic acid and Dexamethasone are dissolved in DMSO to a final concentration of 10 mM for the stock solution. Neochlorogenic acid and/or LPS treatments are performed in a serum-free environment. Neochlorogenic acid's effects on lipopolysaccharide (LPS)-stimulated BV2 microglial cells' ability to survive are evaluated. Neochlorogenic acid (10, 50, and 100 μM) and LPS (4 μg/ml) are applied to the cells either alone or in combination for 24 hours. The positive control is dexamethasone (10 μM). The MTT assay is used to confirm cell viability. The samples were incubated for 3 hours at 37°C after the medium was taken out of the wells and MTT was added. DMSO was used to dissolve the formazan crystals, and a microplate reader was used to measure the absorbance values at 540 nm[1].
|
| References |
| Molecular Formula |
C₁₆H₁₈O₉
|
|---|---|
| Molecular Weight |
354.31
|
| Exact Mass |
354.09508215
|
| CAS # |
906-33-2
|
| Related CAS # |
Chlorogenic acid;327-97-9
|
| Appearance |
Solid
|
| SMILES |
C1[C@H]([C@@H]([C@@H](C[C@]1(C(=O)O)O)OC(=O)/C=C/C2=CC(=C(C=C2)O)O)O)O
|
| InChi Key |
CWVRJTMFETXNAD-NXLLHMKUSA-N
|
| InChi Code |
InChI=1S/C16H18O9/c17-9-3-1-8(5-10(9)18)2-4-13(20)25-12-7-16(24,15(22)23)6-11(19)14(12)21/h1-5,11-12,14,17-19,21,24H,6-7H2,(H,22,23)/b4-2+/t11-,12-,14+,16-/m1/s1
|
| Chemical Name |
(1R,3R,4S,5R)-3-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid
|
| Synonyms |
Neochlorogenate; 5-O-Caffeoylquinic acid; trans-5-O-Caffeoylquinic acid; Neochlorogenic acid
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 70~100 mg/mL (197.6~282.2 mM)
H2O: 2 mg/mL (~5.6 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (5.87 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 4 mg/mL (11.29 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8224 mL | 14.1119 mL | 28.2239 mL | |
| 5 mM | 0.5645 mL | 2.8224 mL | 5.6448 mL | |
| 10 mM | 0.2822 mL | 1.4112 mL | 2.8224 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
